Virological Predictors of Response to Retreatment in Hepatitis C Genotype 2 Infected PatientsReportar como inadecuado




Virological Predictors of Response to Retreatment in Hepatitis C Genotype 2 Infected Patients - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Background-Aims

The impact of virological factors and interleukin-28B IL-28B genetic variants on retreatment of hepatitis C virus genotype 2 HCV-2 treatment-experienced patients remains unknown.

Methods

On-treatment virological responses and IL-28B rs8099917 genotype were determined in 46 HCV-2 treatment-experienced patients 42 previous relapsers; four previous non-responders retreated with 24-week peginterferon-ribavirin.

Results

Forty 87.0% patients carried the rs8099917 TT genotype and 6 patients 13.0% carried the TG-GG genotype. The sustained virological response SVR; seronegativity of HCV RNA throughout 24 weeks of the post-treatment follow-up period rate was 71.7%. Compared with previous non-responders, previous relapsers had a significantly higher SVR rate 78.6% vs. 0%, P = 0.004 and a lower relapse rate 17.5% vs. 100%, P = 0.04. All the previous non-responders were with the rs8099917 TT genotype. As for those who relapsed, treatment responses, including the rates of rapid virological response RVR, 80.6% vs. 66.7%, P = 0.59, early virological response EVR, 97.2% vs. 83.3%, P = 0.27, end-of-treatment virological response 97.2% vs. 83.3%, P = 0.27 and SVR 80.6% vs. 66.7%, P = 0.59 and relapse rate 17.1% vs. 20.0%, P = 1 did not differ significantly between patients with the rs8099917 TT and those with the non-TT genotype. Multivariate analysis revealed that the most important factor predictive of an SVR in the retreatment of HCV-2 was previous relapse; the only factor predictive of an SVR for previous relapsers was the achievement of an EVR. Compared with the achievement of a RVR, the attainment of an EVR was more accurate in predicting an SVR 88% vs. 74%.

Conclusions

Peginterferon-ribavirin is effective in the retreatment of HCV-2 relapsers, especially among those who achieved an EVR.



Autor: Chung-Feng Huang, Chia-Yen Dai , Ming-Lun Yeh, Jee-Fu Huang, Ching-I Huang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Liang-

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados